Corrigendum to "Delgocitinib ointment, a topical Janus kinase inhibitor, in adult patients with moderate to severe atopic dermatitis: A phase 3, randomized, double-blind, vehicle-controlled study and an open-label, long-term extension study.2020;82:823-31

Journal of the American Academy of Dermatology ◽

10.1016/j.jaad.2021.07.010 ◽

2021 ◽

Keyword(s):

Atopic Dermatitis ◽

Kinase Inhibitor ◽

Janus Kinase ◽

Controlled Study ◽

Severe Atopic Dermatitis ◽

Phase 3 ◽

Double Blind ◽

Janus Kinase Inhibitor

Download Full-text

Delgocitinib ointment, a topical Janus kinase inhibitor, in adult patients with moderate to severe atopic dermatitis: A phase 3, randomized, double-blind, vehicle-controlled study and an open-label, long-term extension study

Journal of the American Academy of Dermatology ◽

10.1016/j.jaad.2019.12.015 ◽

2020 ◽

Vol 82 (4) ◽

pp. 823-831 ◽

Author(s):

Hidemi Nakagawa ◽

Osamu Nemoto ◽

Atsuyuki Igarashi ◽

Hidehisa Saeki ◽

Hironobu Kaino ◽

...

Keyword(s):

Atopic Dermatitis ◽

Kinase Inhibitor ◽

Janus Kinase ◽

Controlled Study ◽

Severe Atopic Dermatitis ◽

Phase 3 ◽

Double Blind ◽

Janus Kinase Inhibitor

Download Full-text

Efficacy and safety of topical delgocitinib (JTE-052), janus kinase inhibitor, in Japanese adult patients with moderate-to-severe atopic dermatitis: A phase III, randomized, double-blind, vehicle-controlled study

Journal of the American Academy of Dermatology ◽

10.1016/j.jaad.2019.06.737 ◽

2019 ◽

Vol 81 (4) ◽

pp. AB199

Keyword(s):

Atopic Dermatitis ◽

Kinase Inhibitor ◽

Janus Kinase ◽

Phase Iii ◽

Controlled Study ◽

Severe Atopic Dermatitis ◽

Efficacy And Safety ◽

Japanese Adult ◽

Double Blind ◽

Janus Kinase Inhibitor

Download Full-text

Delgocitinib ointment in pediatric patients with atopic dermatitis: a phase 3, randomized, double-blind, vehicle-controlled study and a subsequent open-label, long-term study

Journal of the American Academy of Dermatology ◽

10.1016/j.jaad.2021.06.014 ◽

2021 ◽

Author(s):

Hidemi Nakagawa ◽

Osamu Nemoto ◽

Atsuyuki Igarashi ◽

Hidehisa Saeki ◽

Kenji Kabashima ◽

...

Keyword(s):

Atopic Dermatitis ◽

Pediatric Patients ◽

Controlled Study ◽

Phase 3 ◽

Double Blind ◽

Long Term Study

Download Full-text

Efficacy and safety of topical delgocitinib (JTE-052), janus kinase inhibitor, in Japanese pediatric patients with atopic dermatitis: A phase II, randomized, double-blind, vehicle-controlled study

Journal of the American Academy of Dermatology ◽

10.1016/j.jaad.2019.06.224 ◽

2019 ◽

Vol 81 (4) ◽

pp. AB53

Keyword(s):

Atopic Dermatitis ◽

Phase Ii ◽

Pediatric Patients ◽

Kinase Inhibitor ◽

Janus Kinase ◽

Controlled Study ◽

Efficacy And Safety ◽

Double Blind ◽

Janus Kinase Inhibitor

Download Full-text

25094 Delgocitinib ointment in pediatric patients with atopic dermatitis: A phase 3, randomized, double-blind, vehicle-controlled study and an open-label, long-term extension study

Journal of the American Academy of Dermatology ◽

10.1016/j.jaad.2021.06.235 ◽

2021 ◽

Vol 85 (3) ◽

pp. AB52

Author(s):

Hidemi Nakagawa ◽

Osamu Nemoto ◽

Atsuyuki Igarashi ◽

Hidehisa Saeki ◽

Kenji Kabashima ◽

...

Keyword(s):

Atopic Dermatitis ◽

Pediatric Patients ◽

Extension Study ◽

Controlled Study ◽

Phase 3 ◽

Download Full-text

Long‐term safety and efficacy of delgocitinib ointment, a topical Janus kinase inhibitor, in adult patients with atopic dermatitis

The Journal of Dermatology ◽

10.1111/1346-8138.15173 ◽

2019 ◽

Vol 47 (2) ◽

pp. 114-120 ◽

Author(s):

Hidemi Nakagawa ◽

Osamu Nemoto ◽

Atsuyuki Igarashi ◽

Hidehisa Saeki ◽

Ryusei Murata ◽

...

Keyword(s):

Atopic Dermatitis ◽

Kinase Inhibitor ◽

Janus Kinase ◽

Adult Patients ◽

Janus Kinase Inhibitor ◽

Safety And Efficacy

Download Full-text

OP0202 Efficacy and safety of tofacitinib, an oral janus kinase inhibitor, in patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: opal beyond, a randomised, double-blind, placebo-controlled, phase 3 trial

10.1136/annrheumdis-2017-eular.2443 ◽

2017 ◽

Author(s):

DD Gladman ◽

WFC Rigby ◽

VF Azevedo ◽

F Behrens ◽

R Blanco ◽

...

Keyword(s):

Tumour Necrosis ◽

Kinase Inhibitor ◽

Janus Kinase ◽

Inadequate Response ◽

Efficacy And Safety ◽

Phase 3 ◽

Double Blind ◽

Janus Kinase Inhibitor ◽

Double Blind Placebo ◽

Necrosis Factor

Download Full-text

OP0047 Baricitinib, an Oral Janus Kinase Inhibitor, in the Treatment of Rheumatoid Arthritis: Safety and Efficacy in Open-Label, Long-Term Extension Study

Annals of the Rheumatic Diseases ◽

10.1136/annrheumdis-2013-eular.252 ◽

2013 ◽

Vol 72 (Suppl 3) ◽

pp. A65.2-A66 ◽

Author(s):

P. Taylor ◽

M. C. Genovese ◽

E. Keystone ◽

D. Schlichting ◽

S. Beattie ◽

...

Keyword(s):

Rheumatoid Arthritis ◽

Kinase Inhibitor ◽

Janus Kinase ◽

Extension Study ◽

Janus Kinase Inhibitor ◽

Safety And Efficacy

Download Full-text

Tofacitinib (CP-690,550), an oral Janus kinase inhibitor, improves patient-reported outcomes in a phase 2b, randomized, double-blind, placebo-controlled study in patients with moderate-to-severe psoriasis

Journal of the European Academy of Dermatology and Venereology ◽

10.1111/jdv.12081 ◽

2013 ◽

Vol 28 (2) ◽

pp. 192-203 ◽

Author(s):

C. Mamolo ◽

J. Harness ◽

H. Tan ◽

A. Menter

Keyword(s):

Patient Reported Outcomes ◽

Kinase Inhibitor ◽

Severe Psoriasis ◽

Janus Kinase ◽

Controlled Study ◽

Double Blind ◽

Janus Kinase Inhibitor ◽

Double Blind Placebo ◽

Patient Reported

Download Full-text

A multicentre, randomized, double-blind, controlled study of long-term treatment with 0.1% tacrolimus ointment in adults with moderate to severe atopic dermatitis

British Journal of Dermatology ◽

10.1111/j.1365-2133.2005.06592.x ◽

2005 ◽

Vol 152 (6) ◽

pp. 1282-1289 ◽

Author(s):

S. Reitamo ◽

J.P. Ortonne ◽

C. Sand ◽

F. Cambazard ◽

T. Bieber ◽

...

Keyword(s):

Atopic Dermatitis ◽

Term Treatment ◽

Controlled Study ◽

Severe Atopic Dermatitis ◽

Double Blind ◽

Tacrolimus Ointment ◽

Long Term Treatment

Download Full-text